ReviewThe international journal of neuropsychopharmacology2021
Mechanisms Underlying the Comorbidity of Schizophrenia and Type 2 Diabetes Mellitus.
Review in The international journal of neuropsychopharmacology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 44 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
44 citing papers in PubMed, 2 syntheses or guidelines pooled it, 75 citations in OpenAlex.
- A meta-analysis of the incidence proportion of obesity and associated risk factors in patients with schizophrenia.Frontiers in psychiatry · 2026Pooled it
- Schizophrenia and type 2 diabetes risk: a systematic review and meta-analysis.Frontiers in endocrinology · 2024Pooled it
- Sex-specific differences in the relationship between prolactin and glucose metabolism in first-episode schizophrenia.European archives of psychiatry and clinical neuroscience · 2026Article
- Prevalence and Healthcare Costs of Metabolic Disorders Among Individuals with Schizophrenia Following Initiation of Oral Antipsychotic Therapy.PharmacoEconomics - open · 2026Article
- [Mental and neurocognitive diseases and diabetes mellitus (Update 2026)].Wiener klinische Wochenschrift · 2026Review
- MiR-7 in neurological disorders: beyond metabolic dysregulation.Frontiers in neuroscience · 2026Review
- Prevalence and Risk Factors of Comorbid Type 2 Diabetes Mellitus in Adults With Severe Mental Disorders: A Retrospective Study.Alpha psychiatry · 2025Article
- Association between antidiabetic drug targets and psychiatric disorders.Schizophrenia (Heidelberg, Germany) · 2025Article
- Orphan G Protein-Coupled Receptor GPR88: Mapping Its Significance in Central Nervous System Disorders.Molecular neurobiology · 2025Review
- βIV spectrin abundancy, cellular distribution and sensitivity to AKT/GSK3 regulation in schizophrenia.Molecular psychiatry · 2025Article
- Metabolic syndrome in patients with schizophrenia: Underlying mechanisms and therapeutic approaches (Review).Molecular medicine reports · 2025Review
- Metabolic biomarkers of clinical outcomes in severe mental illness (METPSY): protocol for a prospective observational study in the Hub for metabolic psychiatry.BMC psychiatry · 2025Article
- Meta-analyses of epigenetic age acceleration and GrimAge components of schizophrenia or first-episode psychosis.Schizophrenia (Heidelberg, Germany) · 2024Article
- Validation of the Comprehensive and Brief International Classification of Functioning, Disability and Health Core Sets for Schizophrenia from the Perspective of Individuals Diagnosed with the Disorder: A Worldwide Study Using Focus Groups.Behavioral sciences (Basel, Switzerland) · 2024Article
- Psychosis Associated With Hyperglycemia in a Female Patient With Type 1 Diabetes Mellitus: A Case Report.Cureus · 2024Article
- Integrating Electronic Health Records and Polygenic Risk to Identify Genetically Unrelated Comorbidities of Schizophrenia That May Be Modifiable.Biological psychiatry global open science · 2024Article
- A network of transcriptomic signatures identifies novel comorbidity mechanisms between schizophrenia and somatic disorders.Discover mental health · 2024Article
- Genomic insights into the comorbidity between type 2 diabetes and schizophrenia.Schizophrenia (Heidelberg, Germany) · 2024Article
- Efficacy and Safety of Insulin Degludec/Insulin Aspart versus Biphasic Insulin Aspart 30 in Patients with Type 2 Diabetes: A Meta-Analysis of Randomized Controlled Trials.Iranian journal of public health · 2024Review
- Validity of handgrip strength for assessing cognition and psychotic symptoms in hospitalized patients with stable schizophrenia.PloS one · 2024Article
Corrections and comments
- Commented on by
Authors and funding
7 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The mortality rate of patients with schizophrenia is high, and life expectancy is shorter by 10 to 20 years. Metabolic abnormalities including type 2 diabetes mellitus (T2DM) are among the main reasons. The prevalence of T2DM in patients with schizophrenia may be epidemiologically frequent because antipsychotics induce weight gain as a side effect and the cognitive dysfunction of patients with schizophrenia relates to a disordered lifestyle, poor diet, and low socioeconomic status. Apart from these common risk factors and risk factors unique to schizophrenia, accumulating evidence suggests the existence of common susceptibility genes between schizophrenia and T2DM. Functional proteins translated from common genetic susceptibility genes are known to regulate neuronal development in the brain and insulin in the pancreas through several common cascades. In this review, we discuss common susceptibility genes, functional cascades, and the relationship between schizophrenia and T2DM. Many genetic and epidemiological studies have reliably associated the comorbidity of schizophrenia and T2DM, and it is probably safe to think that common cascades and mechanisms suspected from common genes' functions are related to the onset of both schizophrenia and T2DM. On the other hand, even when genetic analyses are performed on a relatively large number of comorbid patients, the results are sometimes inconsistent, and susceptibility genes may carry only a low or moderate risk. We anticipate future directions in this field.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.